CD40 and neoplasm: Recent studies investigating the combination of CD40 agonists with gemcitabine and nab-paclitaxel in PDAC have shown that tumor extrinsic immune signatures associate with improved outcomes,13,14 consistent with the potential benefit of CD40 agonism.